Core Viewpoint - The company, Innovent Biologics, reported a significant revenue increase driven by the continued growth of its core product, Oubatinib, and strategic partnerships, while also making substantial progress in its clinical pipeline and global expansion efforts [1][3][4]. Financial Performance - For the first half of 2025, the company's revenue grew by 74.3% year-on-year, reaching 730 million RMB, primarily due to the strong sales of Oubatinib and an upfront payment from a licensing agreement with Prolium [1]. - Drug revenue increased by 53.5% year-on-year to 640 million RMB, attributed to Oubatinib's inclusion in the national medical insurance and its expanding patient base [1]. - The company's loss narrowed by 86.7% year-on-year to 36 million RMB, reflecting increased revenue and improved cost efficiency [1]. Research and Development - R&D expenses rose by 6.9% year-on-year to 450 million RMB, focusing on building a differentiated R&D platform and advancing multiple Phase III clinical projects [1][2]. Product Pipeline and Approvals - Oubatinib was approved for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and is included as a Level I recommendation in the CSCO lymphoma treatment guidelines [3]. - Tafasitamab (brand name: Mingnuokai) was approved for treating relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) in combination with lenalidomide, marking it as the first CD19 monoclonal antibody approved for this indication in China [3]. - The BCL2 inhibitor, Mesutoclax (ICP-248), is advancing in two registration clinical studies and has received Breakthrough Therapy Designation, being the first BCL2 inhibitor in China to achieve this status [3]. - The new generation TRK inhibitor, Zurletrectinib (ICP-723), has had its new drug application accepted in China and is under priority review, potentially becoming the first domestically developed TRK inhibitor approved for market [3]. Strategic Partnerships and Global Expansion - The company is expanding its global footprint through strategic collaborations, including a licensing agreement with Prolium for the development and commercialization of the CD20×CD3 bispecific antibody ICP-B02 [4]. - The commercial team has shown strong execution capabilities, leading to increased market penetration and revenue growth for Oubatinib [4]. Leadership in Hematological Oncology - The company is strengthening its leadership position in hematological oncology with Oubatinib, Tafasitamab, and Mesutoclax as cornerstone therapies [5]. - Oubatinib's approval for first-line treatment of CLL/SLL and Tafasitamab's approval for R/R DLBCL enhance the company's product offerings in this field [5]. Autoimmune Disease Pipeline - Oubatinib is being developed as a new treatment option for primary immune thrombocytopenia (ITP), with Phase III clinical trials completed and an application for market approval expected in mid-2026 [11]. - The company is also advancing two TYK2 inhibitors in clinical trials, targeting various autoimmune diseases [12]. ADC Technology Development - The company has developed a differentiated ADC technology platform aimed at creating effective and targeted therapies for cancer treatment [16]. - The first ADC candidate, targeting B7-H3, has received clinical approval and is expected to enter patient trials soon [18][19].

智通财经APP讯，诺诚健华(688428.SH)发布2025年半年度报告，报告期内，公司实现营业收入7.31亿 元，同比增长74.26%。归属于上市公司股东净亏损3009.14万元，归属于上市公司股东的扣除非经常性 损益净亏损8227.13万元，基本每股亏损0.02元。 ...

Core Insights - Nuo Cheng Jian Hua reported a 74.3% year-on-year revenue growth for the first half of 2025, reaching 730 million yuan, driven by the strong performance of its core product, Obinutuzumab (brand name: Yinuokai), and an upfront payment from a licensing agreement with Prolium [1] - The company's drug revenue increased by 53.5% year-on-year to 640 million yuan, attributed to the inclusion of Obinutuzumab in the national medical insurance and its expanding patient base, particularly in the unique indication of marginal zone lymphoma [1] - The company reduced its losses by 86.7% year-on-year to 36 million yuan in the first half of 2025 [1] Financial Performance - Research and development expenses increased by 6.9% year-on-year to 450 million yuan, primarily for building a differentiated R&D platform and advancing more Phase III clinical projects [1] - As of June 30, 2025, the company held approximately 7.68 billion yuan in cash and cash equivalents, which will support the acceleration of multiple Phase III clinical trials and investments in differentiated ADCs and other pipelines [1] Product Pipeline and Strategic Developments - Nuo Cheng Jian Hua made significant progress in its product pipeline, with Obinutuzumab approved for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and listed as a Level I recommendation in the CSCO lymphoma treatment guidelines [2] - The company’s CD19 monoclonal antibody, Tanshuizhu, in combination with Lenalidomide, was approved for treating relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), marking it as the first CD19 monoclonal antibody approved for this indication in China [2] - The BCL2 inhibitor Mesutoclax (ICP-248) is advancing two registration clinical studies and has received Breakthrough Therapy Designation, making it the first BCL2 inhibitor in China to achieve this status [2] Future Outlook - The CEO of Nuo Cheng Jian Hua stated the company aims to accelerate innovation, commercialization, and internationalization, with plans to advance multiple innovative drugs for approval in the next three to five years and to push three to four products for internationalization [3] - The company is also focused on developing five to ten differentiated molecules in preclinical stages [3]

人民财讯8月19日电，诺诚健华(688428)8月19日晚间披露2025年半年报，公司上半年实现营业收入7.31 亿元，同比增长74.26%；归母净利润为-3009.14万元，上年同期亏损2.62亿元。基本每股收益-0.02元。 报告期内，营业收入较上年同期增加，主要系奥布替尼销售量持续增加及达成授权许可确认相关收入所 致，其中药品销售收入增长53.47%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 海外監管公告 本公告乃諾誠健華醫藥有限公司（「本公司」）根據香港聯合交易所有限公司證 券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊登之《2025年半年度報告》、《2025年半 年度報告摘要》、《2025年半年度募集資金存放與實際使用情況的專項報告》、 《關於部分募投項目延期及使用募集資金向全資子公司增資以實施募投項目的 公告》、《關於使用自有資金支付募投項目所需資金並以募集資金等額置換的 公告》、《關於收購控股子公司剩餘股權的公告》、《關於修訂及制定部分公司 治理制度的公告》、《2025年度"提質增效重回報"行動方案的半年度評估報告》、 《中國國際金融股份有限公司關於諾誠健華醫藥有限公司部分募投項目延期及 使用募集資金向全資 ...

Group 1 - The company plans to acquire the remaining 7% equity of its subsidiary Guangzhou Nuo Cheng Jian Hua Pharmaceutical Technology Co., Ltd. for no more than 476 million yuan, using its own funds [1] - Upon completion of the acquisition, the company will hold 100% of the equity in Guangzhou Nuo Cheng Jian Hua, enhancing control over the subsidiary and improving operational and decision-making efficiency [1] - The acquisition aims to reduce management costs and risks, optimize resource allocation, and support the company's strategic development goals [1] Group 2 - In the first half of 2025, the company reported revenue of approximately 731 million yuan, representing a year-on-year increase of 74.26% [1] - The revenue growth is primarily attributed to the continued sales increase of the core product, Aobutini (brand name: Yinuokai), and an upfront payment received from a licensing agreement with Prolium [1] - The company's losses narrowed significantly by 86.7% year-on-year, reducing to 36 million yuan, due to increased revenue and improved cost efficiency [1]

诺诚健华（SH 688428，收盘价：31.81元）8月19日晚间发布半年度业绩报告称，2025年上半年营业收 入约7.31亿元，同比增加74.26%；归属于上市公司股东的净利润亏损约3009万元；基本每股收益亏损 0.02元。 （文章来源：每日经济新闻） ...

中国国际金融股份有限公司 关于诺诚健华医药有限公司 部分募投项目延期及使用募集资金向全资子公司增资以实施募投项目 的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为诺诚健 华医药有限公司（以下简称"公司"）的保荐机构，根据《证券发行上市保荐业务管理 办法》《上海证券交易所科创板股票上市规则》《上市公司募集资金监管规则》《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》及《上海证券交易所上市 公司自律监管指引第 11 号——持续督导》等有关法律、行政法规、部门规章及业务规 则的要求，对诺诚健华医药有限公司部分募投项目延期及使用募集资金向全资子公司增 资以实施募投项目的事项进行了认真、审慎核查，具体情况如下： | 序号 | 项目名称 | 投资总额 | 调整前拟投入募集 | 调整后拟投入募集 | | --- | --- | --- | --- | --- | | | | | 资金金额 | 资金金额 | | 1 | 新药研发项目 | 215,087.40 | 149,422.06 | 149,422.06 | | 2 | 药物研发平台升级项目 | 16,718.87 | ...

关于诺诚健华医药有限公司 使用自有资金支付募投项目所需资金 并以募集资金等额置换的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为诺诚健 华医药有限公司（以下简称"公司"）的保荐机构，根据《证券发行上市保荐业务管理 办法》《上海证券交易所科创板股票上市规则》《上市公司募集资金监管规则》《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》及《上海证券交易所上市 公司自律监管指引第 11 号——持续督导》等有关法律、行政法规、部门规章及业务规 则的要求，对诺诚健华医药有限公司使用自有资金支付募投项目所需资金并以募集资金 等额置换的事项进行了认真、审慎核查，具体情况如下： 一、募集资金基本情况 中国国际金融股份有限公司 公司首次公开发行股票并在科创板上市的注册申请于 2022 年 7 月 15 日经中国证 券监督管理委员会同意注册（证监许可[2022]1524 号《关于同意诺诚健华医药有限公司 首次公开发行股票注册的批复》），公司据此采用向战略投资者定向配售、网下向符合条 件的投资者询价配售和网上向持有上海市场非限售 A 股股份和非限售存托凭证市值的 社会公众投资者定价发 ...

InnoCare Pharma Limited （诺诚健华医药有限公司） 内部审计管理制度 内审部发现公司重大问题或线索，应当立即向审核委员会直接报告。 第五条 审计工作遵循"独立、客观、公正、保密"的原则。 内审部应当保持独立性，不得置于财务部门的领导之下，或者与财 务部门合署办公。 内审部负责人的考核，应当经由审核委员会参与发表意见。 内审部履行职责所必需的经费由公司予以保证。 1 第七条 审计对象 第八条 审计范围 其中，离任审计范围主要包括：高级管理层及高精尖人才， 副总监以上由高级管理层及人力资源部讨论重要性后决定 是否进行离任审计。 第九条 内部审计权限 2 第一条 为规范 InnoCare Pharma Limited（诺诚健华医药有限公司）（以下 简称"公司"）经营管理，加强内部控制与审计监督，保障公司财 产的安全、完整，确保公司持续健康发展，根据相关法律法规，制 定本内部审计管理制度（以下简称"本制度"）。 第二条 本制度所称内部审计，是指通过一定的方法对公司的经营状况进行 综合评价，并提出合理化建议。 第三条 内部审计的目的是促进公司内部控制制度的建立与健全，改善经营 管理，规避经营风险， ...